Hematology

Leukemia

View All

OncUpdates episode 4 features experts discussing FLT3-Positive AML targeted therapy from diagnosis through long-term management.

Leukemia

07/28/2026

Ep. 4: FLT3-Mutated AML: Targeted Therapy From Diagnosis Through Long-Term Management

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

OncUpdates episode 3 featuring experts discussing FLT3-mutated AML, maintenance therapy, triplet regimens, and relapse management.

Leukemia

07/27/2026

Ep. 3: FLT3-Mutated AML: Maintenance Therapy, Triplet Regimens, and Relapse Management

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Experts discuss FLT3 inhibitors expanding treatment options in acute myeloid leukemia at OncUpdates.

Leukemia

07/24/2026

Ep. 2: FLT3 Inhibitors Continue to Expand Treatment Opportunities in Acute Myeloid Leukemia

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of five medical professionals discussing FLT3-mutated AML treatment strategies in a clinical setting.

Leukemia

07/23/2026

Ep. 1: Optimizing FLT3-Mutated AML Through Precision Testing and Targeted Therapy

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Group of five leukemia specialists discussing FLT3 inhibitors in AML treatment, featuring Dr. Nicholas Short, Dr. Uma Borate, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Naval Dayer.

Leukemia

07/13/2026

Leukemia Specialists Review the Role of FLT3 Inhibitors Across AML Treatment Settings

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

MDS

View All

Group photo of five medical professionals discussing personalized therapy decisions in myelodysplastic syndromes.

MDS

08/07/2026

Ep. 4: Personalizing Therapy Decisions in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Panel of five medical experts discussing managing imetelstat toxicities in lower-risk MDS during OncUpdates episode 3.

MDS

08/04/2026

Ep. 3: Managing Imetelstat Toxicities in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Panel of five medical experts discussing treatment sequencing in lower-risk MDS at OncUpdates.

MDS

08/01/2026

Ep. 2: Imetelstat, Luspatercept, and ESAs: Treatment Sequencing in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Group photo of five medical professionals discussing next-generation sequencing and IPSS-M in lower-risk MDS for OncUpdates episode 1.

MDS

07/29/2026

Ep. 1: The Growing Role of Next-Generation Sequencing and IPSS-M in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Evolving approaches in low-risk myelodysplastic syndromes with expert doctors Dr. Yasmin Abaza, Dr. Thomas LeBlanc, Dr. Hetty Carraway, Dr. Rahul Gosain, and Dr. Amer Zeidan.

MDS

07/28/2026

The Role of Imetelstat in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Panel of four medical experts discussing managing side effects of Luspatercept in a professional setting.

MDS

06/25/2026

Managing Side Effects of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Image featuring Dr. Jamile M. Shammo, Dr. Tiffany Tanaka, Dr. Rohit Gosain, Dr. Amer Zeidan, and Dr. Christopher Benton discussing low-risk MDS and clinical trial data.

MDS

06/24/2026

Luspatercept: Clinical Trial Data and Lessons for Low-Risk MDS

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Panel of four medical experts discussing recent advancements in defining, diagnosing, and staging myelodysplastic syndromes (MDS) for oncology updates.

MDS

06/23/2026

Recent Advancements in Defining, Diagnosing, and Staging MDS

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Panel of four hematology experts discussing Luspatercept and low-risk MDS treatment strategies in a medical webinar.

MDS

06/22/2026

Treating Low-Risk MDS After the Introduction of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Expert panel discussing recent advances in Luspatercept treatment for LR-MDS, highlighting evolving strategies and clinical insights.

MDS

06/12/2026

The Treatment Paradigm for Low-Risk MDS and the Impact of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Multiple Myeloma

View All

Panel discussion on partnerships and outpatient strategies for bispecifics in multiple myeloma with Dr. S. Vincent Rajkumar, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Beth Faiman, and Dr. Rafael Fonseca.

Multiple Myeloma

07/10/2026

Ep 4. Community Perspective: Partnerships and Outpatient Strategies for Bispecifics in Multiple Myeloma

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

OncUpdates episode 3 features Dr. S. Vincent Rajkumar discussing managing side effects of BCMA bispecifics and Talquetamab in myeloma treatment.

Multiple Myeloma

07/09/2026

Ep 3. Managing Side Effects BCMA Bispecifics and Talquetamab in Myeloma

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

OncUpdates Episode 2 features Dr. S. Vincent Rajkumar discussing bispecifics: MajesTEC-3, MajesTEC-9, and MonumenTAL-3 with expert panel.

Multiple Myeloma

07/08/2026

Ep 2. The Advent of Bispecifics: MajesTEC-3, MajesTEC-9, and MonumenTAL-3

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

Dr. S. Vincent Rajkumar and colleagues discuss a new algorithm for second-line treatment of multiple myeloma in a medical webinar.

Multiple Myeloma

07/07/2026

Ep 1. The New Algorithm for Second-Line Treatment of Multiple Myeloma

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

CAR T-cell therapy in multiple myeloma with insights from ASCO 2026, featuring experts Dr. Binod Dhakal, Dr. Surbhi Sidana, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Ajai Chari.

Multiple Myeloma

06/27/2026

CAR T in Myeloma: Earlier Use and Sequencing Insights from ASCO 2026

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Group of medical professionals discussing evolving treatment landscape in second-line and beyond multiple myeloma, with cityscape background.

Multiple Myeloma

06/26/2026

Evolving Treatment Landscape in Second-Line and Beyond Multiple Myeloma

Beth Faiman, CNP, PhDRafael Fonseca, MDS. Vincent Rajkumar, MDRahul Gosain, MD, MBARohit Gosain, MD

Group of medical professionals discussing real-world safety and care coordination for CAR T-cell therapy, featuring Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Surbhi Sidana, Dr. Ajai Chari, and Dr. Binod.

Multiple Myeloma

06/12/2026

Multiple Myeloma Experts Highlight Real-World Safety and Care Coordination Following CAR T-Cell Therapy

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of multiple myeloma experts discussing CAR T and BCMA therapies, including Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Surbhi Sidana, Dr. Binod Dhakal, and Dr. Ajai Chari, during a virtual conferenc.

Multiple Myeloma

06/11/2026

CAR T vs BCMA-Directed Bispecific Antibodies: Multiple Myeloma Experts Share Sequencing Insights

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

$Innovative CAR T-cell therapy for relapsed or refractory multiple myeloma, featuring expert insights from Dr. Surbhi Sidana, Dr. Rahul Gosain, Dr. Ajai Chari, and Dr. Binod Dhakal.$

Multiple Myeloma

06/10/2026

CAR T-Cell Therapy Moves Earlier in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Close-up of Verenzo (bevemacil) 50 mg tablets in packaging, used for erectile dysfunction treatment, displayed on a white background.

Multiple Myeloma

06/05/2026

CAR T in Myeloma: Earlier Use and Sequencing Insights from ASCO 2026

Binod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Polycythemia Vera

View All

Panel discussion on treatment options and future research in polycythemia vera featuring Dr. Anand Patel, Dr. Aaron Gerds, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Anthony Hunter.

Polycythemia Vera

06/11/2026

Treatment Selection and Future Directions in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of four doctors discussing molecular responses and long-term disease control in polycythemia vera, highlighting recent research and treatment strategies.

Polycythemia Vera

06/10/2026

Molecular Responses and Long-Term Disease Control in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of four doctors discussing treatment strategies for polycythemia vera, focusing on optimizing ropeginterferon therapy, with a city skyline background.

Polycythemia Vera

06/09/2026

Optimizing Ropeginterferon Use in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of four doctors discussing current treatment paradigms and the emerging role of Ropiginterferon in polycythemia vera (PV) at OncUpdates.

Polycythemia Vera

06/08/2026

Current Treatment Paradigms and the Emerging Role of Ropeginterferon Alfa-2b-njft in PV

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Experts discuss the role of Ropoginterferon Alfa-2b in treating Polycythemia Vera, highlighting recent clinical insights and therapeutic strategies.

Polycythemia Vera

05/31/2026

Clinical Insights: Role of Ropeginterferon Alfa-2b-njft in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Expert panel discussing managing fatigue and phlebotomy burden in pulmonary embolism patients using Rusteride at OncUpdates conference.

Polycythemia Vera

01/10/2026

Ep. 4: Managing Fatigue and Phlebotomy Burden in PV With Rusfertide

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Managing Hematocrit and Symptoms in PV: Dose Titration Strategies for Rusfertide.

Polycythemia Vera

01/08/2026

Ep. 3: Managing Hematocrit and Symptoms in PV: Dose-Titration Strategies for Rusfertide

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

1. A group of medical researchers and doctors discussing cancer treatment algorithms in a professional conference setting.

Polycythemia Vera

01/06/2026

Ep. 2: Integrating Rusfertide Into the Polycythemia Vera Treatment Algorithm

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Innovative hematocrit control approaches in polycythemia vera presented by leading oncology experts for improved patient management.

Polycythemia Vera

01/02/2026

Ep. 1: Clinical Insights: New Approaches to Hematocrit Control in Polycythemia Vera

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Polycythemia Vera management insights, hematocrit control, and clinical treatment strategies by Dr. Andrew Kuykendall, Dr. Aaron Gerds, Dr. Talha Badar, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Polycythemia Vera

12/22/2025

Clinical Insights: VERIFY Trial Shows Rusfertide’s Potential to Transform PV Treatment (Full Video)

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD